A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies

This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with relapsed/refractory (R/R) B-cell malignancies.

NCT Number	NCT07476378
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences Collaborators: MagicTime Medicine
Conditions	Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Follicular, Lymphoma, Mantle-Cell, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Lymphoma, B-Cell, Marginal Zone, Transformed Follicular Lymphoma (TFL)
Enrollment	69 participants
Start Date	2026-03
Primary Completion	2028-01 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-03-17